Briciclib is primarily utilized in the field of oncology as a cyclin-dependent kinase (CDK) inhibitor. It is being investigated for its potential to treat various types of cancer by targeting and inhibiting specific CDKs that play a crucial role in cell cycle regulation. By doing so, it aims to halt the proliferation of cancer cells, particularly in cases where abnormal cell division is driven by dysregulated CDK activity. Research is ongoing to evaluate its efficacy in clinical trials, focusing on its ability to enhance the effectiveness of existing cancer therapies or serve as a standalone treatment. Its application is particularly promising in cancers that are resistant to conventional treatments, offering a new avenue for therapeutic intervention.